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Abstract
Background: The molecular characteristics and the clinical disease course of bladder cancer (BC) in young patients
remain largely unresolved. All patients are monitored according to an intensive surveillance protocol and we aim
to gain more insight into the molecular pathways of bladder tumors in young patients that could ultimately
contribute to patient stratification, improve patient quality of life and reduce associated costs. We also determined
whether a biomarker-based surveillance could be feasible.
Case Presentation: We report a unique case of a 26-year-old Caucasian male with recurrent non-muscle invasive
bladder tumors occurring at a high frequency and analyzed multiple tumors (maximal pTaG2) and urine samples of
this patient. Analysis included FGFR3 mutation detection, FGFR3 and TP53 immunohistochemistry, mircosatellite
analysis of markers on chromosomes 8, 9, 10, 11 and 17 and a genome wide single nucleotide polymorphism-array
(SNP). All analyzed tumors contained a mutation in FGFR3 and were associated with FGFR3 overexpression. None of
the tumors showed overexpression of TP53. We found a deletion on chromosome 9 in the primary tumor and this
was confirmed by the SNP-array that showed regions of loss on chromosome 9. Detection of all recurrences was
possible by urinary FGFR3 mutation analysis.
Conclusions: Our findings would suggest that the BC disease course is determined by not only a patient’s age,
but also by the molecular characteristics of a tumor. This young patient contained typical genetic changes found
in tumors of older patients and implies a clinical disease course comparable to older patients. We demonstrate
that FGFR3 mutation analysis on voided urine is a simple non-invasive method and could serve as a feasible follow-
up approach for this young patient presenting with an FGFR3 mutant tumor.
Background
Bladder cancer (BC) is a disease of the elderly with a
peak incidence in the sixth decade of life. Tumors are
sporadically found under the age of 40 (1-4%) and most
young patients present with tumors of low stage and
grade [1-4]. Conflicting results have been found con-
cerning the natural history and prognosis of bladder
tumors in young patients. The small number of cases
and the definition of “young” with age ranging from
5-45 years may be responsible for this variation [2,3,5,6].
Evidence is accumulating that there is a difference in
the natural history of patients under the age of 20 and
patients between 30-50 years of age. Patients <20 years
mostly have tumors with a low recurrence rate, a favor-
able clinical outcome and few genetic alterations, while
patients between 30-50 years have a disease course com-
parable to older patients [7].
Almost 80% of the BC patients will present with non-
muscle invasive disease (NMI-BC). Treatment is by
trans-urethral resection of the tumor, but almost 70% of
the patients will have at least one recurrence within five
years and 10-20% will progress to muscle-invasive dis-
ease. After the first tumor resection all age groups of
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patients are monitored according to an intensive surveil-
lance protocol that includes 3-monthly cystoscopies the
first two years, followed by less frequent observations if
a patient stays recurrence free. The main disadvantages
of the current protocol are life-long invasive and costly
cystoscopic monitoring of patients causing physical dis-
comfort and sexual dysfunction [8].
To our knowledge there are only few studies that
investigated the molecular changes in bladder tumors of
young patients. Identifying the molecular pathways of
these tumors could define a subset of patients and redir-
ect patient management towards a new patient friendly
and individualized follow-up protocol. One of the most
promising markers associated with NMI bladder tumors
is the mutation status of the Fibroblast Growth Factor
Receptor-3 (FGFR3). Mutations in FGFR3 have been
associated with BC tumors of low stage and grade and
patients having a favorable prognosis [9]. We have
recently shown that FGFR3 mutation analysis on voided
urine of NMI-BC patients with a mutation in FGFR3 is
a non-invasive inexpensive tool for patient surveillance
(Zuiverloon et al. submitted). Additionally, multiple stu-
dies report on the use of microsatellite analysis (MA)
for detection of loss-of-heterozygosity (LOH) as a diag-
nostic marker. LOH detected by MA is mainly located
on chromosomes 8, 9, 10, 11, 13 and 17 and these losses
have been associated with stage, grade, invasive growth,
recurrent disease and progression. In the present study
we analyzed multiple tumor and urine samples of a
unique young patient for FGFR3 mutation status, LOH,
FGFR3 and TP53 expression and performed a genome
wide single nucleotide polymorphism-array (SNP). Since
this patient presented with multiple recurrences within
a short time-span we determined retrospectively
whether FGFR3 mutation detection could be a feasible
follow-up approach.
Case presentation
We report a unique case of a 26-year-old Caucasian
male with recurrent non-muscle invasive bladder tumors
occurring at a high frequency. The patient presented at
first in March 2007 with macroscopic hematuria for a
few weeks. He received a total of 5 trans-urethral resec-
tions of the multifocal bladder tumors within 2 years,
highest stage and grade being TaG2. The first three
resections included an average of 15 papillary tumors
and the last two resections included 3 tumors. The
patient received two direct post-operative intravesical
instillations of epirubicin. Additionally, our patient initi-
ally received adjuvant intravesical immunotherapy with
bacillus calmette-guérin (BCG) in 2008, but switched to
mitomycin-C (MMC) in 2009 for maintenance due to
complications. A CT-scan of the pelvis and abdomen
demonstrated no evidence of upper urinary tract lesions,
no signs of urolithiasis, nodal or distant metastases.
There was no family history of bladder cancer and
intoxications included a smoking status of 5.5 pack-
years (one pack-year = one pack of cigarettes a day for
one year ~20 cigarettes a day for one year). There was
no indication of any contact with aromatic amines. The
patient worked as a soldier in Bosnia in 2001 and 2003
where he was part of a recovery team driving a diesel
armed-truck. Tasks of the recovery team included clean-
ing of remaining ammunition enforced with depleted
uranium (DU) and military equipment wreckage.
Methods
Tissue samples
Tumor tissue was obtained from formalin-fixed, paraf-
fin-embedded samples. Tumor sections were selected by
pathological examination to contain a minimum amount
of 80% tumor cells and sections were manually dissected
from 4 μ slides. Samples were first deparaffinized and
DNA was extracted using the Qiagen Dneasy blood and
tissue kit (Qiagen, GmbH, Hilden, Germany) according
to the manufacturer’s protocol.
Urine samples
Freshly voided urine (10-100 ml) was collected prior to
a cystoscopy or trans-urethral resection of the tumor
and stored at 4°C until transportation to the department
of Pathology at Erasmus MC, Rotterdam. Urine was
spun down for 10’ at 3000 rpm (1500 × g). Cell pellets
were washed twice with 10 ml of Phosphate-buffered
saline (PBS) and spun down for 10’ at 3000 rpm. Pellets
were resuspended in 1 ml of PBS, transferred to an
eppendorf vial and spun down for 5’ at 6000 rpm (3000
× g). Supernatant was discarded and the cell pellet was
stored at -20°C until DNA isolation. DNA was extracted
using the QiAamp DNA mini-kit (Qiagen GmbH,
Hilden, Germany) according to the manufacturer’s
protocol.
Fibroblast growth factor receptor 3 mutation analysis
The FGFR3 mutation detection assay was performed as
described previously by van Oers et al. [10]. In short a
multiplex PCR of the three regions that contain the
most frequent FGFR3 mutations (exon 7, 10 and 15)
was performed. This was followed by a single nucleo-
tide polymorphism analysis using probes that anneal to
the PCR product adjacent to the mutation site. Probes
were extended with a labeled dideoxynucleotide and
the products were analyzed on an automatic sequencer
(ABI PRISM 3130 XL Genetic Analyzer, Applied Bio-
systems) with the label indicating the presence or
absence of a mutation. Genescan Analysis Software
version 3.7 (Applied Biosystems) was used for analysis
of the data.
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Microsatellite analysis
Microsatellite analysis was performed as described by
van der Aa et al. [11]. Markers used for detection of
LOH were: D8S1130, D81125, D8S1107, D8S1109,
D8S1145, D9S1118, D9S252, D9S304, D9S299, D9S752,
D9S930, G10693, D10S1225, D11S1999, D11S1981 and
D17S969.
FGFR3 and TP53 immunohistochemistry
Bladder tumors were fixed in 10% buffered formaldehyde,
embedded in paraffin, 4 micrometer sections were
mounted on a coated glass slide (Starfrost Knittel-Glaeser
D38114 Braunschweig Germany). Haematoxylin-Eosin
was used as a general stain and immunohistochemistry
was performed with rabbit polyclonal antibody anti-
human FGFR3 (Santa Cruz Biotechnology INC) and
monoclonal mouse anti-human P53 protein clone D-07
(Dakocytomation, Denmark A/S). Antigen retrieval by
microwave heating in TRIS-EDTA buffer pH 9.0 was
used and endogenous peroxidase was removed by 0.30%
H2O2 in PBS/TWEEN. Pretreatment with blocking buffer
PROTIFAR 0.5% in PBS/TWEEN was used prior to the
overnight incubation at 4°C with the primary antibody.
Visualization was done by Dako Real Envision Detection
system peroxidase/DAB+ (Dakocytomation, Denmark A/
S), containing anti-mouse and anti-rabbit antibodies,
according to the manufacturer’s protocol. Counterstain-
ing was done with haematoxylin (Klinipath 6921 GX,
Duiven, The Netherlands). Expression of FGFR3 was
scored in a semi-quantitaive scoring system: 0 = all
tumor cells negative, 1 = faint positivity of in some or all
cells, 2 = weak but extensive positivity and 3 = strong
positivity/overexpression (regardless of extent). TP53
overexression was scored if >10% of the cells stained
positive. As a reference normal urothelium was analyzed
for FGFR3 and TP53 protein expression. Reference sec-
tions of known high and low expressions levels of FGFR3
and TP53 were included in the staining runs.
Infinium HumanHap370CNV Genome wide SNP array
For Infinium HumanHap370CNV Genotyping BeadChip
SNP array analysis we used 750 ng of patient DNA and
followed the protocol as described by the manufacturer
(Illumina Inc., San Diego, CA, USA). We used Illumina
BeadStudio software to extract data. The Nexus CGH
Plug-in for CNV Analysis from BioDiscovery (BioDis-
covery Inc., El Segundo, CA, USA) was used to export
Illumina CNV data to Nexus Copy Number version 4.0.
Arrays were processed using the built-in Rank Segmen-
tation algorithm.
Results and discussion
Young patients rarely present with BC and there are
multiple studies that indicate a good clinical disease
course where patients present with solitary tumors and
a low recurrence and progression rate. Since BC patients
are monitored cystoscopically according to an intensive
surveillance protocol, gaining more insight into the
molecular pathways of BC tumors in young patients
could define a subset of patients that can be monitored
less frequently, hereby improving patient quality of life
and reducing associated costs.
We presented a unique case of a 26-year-old male
with multiple multifocal NMI bladder tumors recurring
at a high frequency. After starting intravesical mainte-
nance therapy with MMC the recurrence rate decreased
and up to date the patient stayed recurrence free. Mole-
cular analysis of the primary tumor revealed an S249C
mutation in FGFR3 (Figure 1B) and overexpression of
FGFR3 (Figure 2B). LOH on chromosome 9 was
detected by MA and confirmed by the genome wide
SNP array analysis. We also found other regions of loss
and gain that are considered minor when compared to
tumors of the same stage and grade (Figure 3). There
was no increased expression of TP53 (Figure 2C).
Hence, this young patient appears to have the typical
genetic changes found in older patients with NMI-BC.
This implies that the patient could have a disease
course comparable to older patients and warrants regu-
lar controls due to the risk of additional recurrences or
progression. These findings combined with previous
studies suggest that not only a patient’s age, but also
the molecular characteristics of the tumor determine
the clinical disease course. Since it takes time to accu-
mulate typical genetic changes involved in BC - e.g.
mutations in FGFR3 and TP53 and LOH on chromo-
somes 8, 9, 10, 11, 17- leading to tumor formation,
most BC patients will present at an older age. Possible
explanations are that older patients have a longer expo-
sure time to BC associated exogenous risk factors and
secondly that pathophysiological changes in elderly
causing urinary stasis in the bladder due to urine reten-
tion lead to an increased exposure to carcinogenic
substances. We suggest that this could be the reason
why tumors of young BC patients mostly have few
genetic alterations and may represent a biologically
distinct group of tumors with an overall good clinical
disease course (Figure 4A). This is in concordance with
one of the few molecular studies on BC in patients <19
years (n = 14) that found no mutations in FGFR3, no
deletions on chromosome arms 9p, 9q or 17p, no MSI
and only one mutation in TP53 [7]. On the other hand
other clinical studies of patients <40 years demonstrate
a disease course comparable to older patients with
typical aggressive behavior in the young presenting with
a primary muscle invasive tumor, but unfortunately no
molecular analyses of these tumors have been
performed [2,5,12,13].
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Figure 1 FGFR3 mutation detection on urinary derived DNA. FGFR3 mutation analysis of an FGFR3 tumor without a mutation (A), mutation
S249C on tumor DNA (B) and urinary derived DNA (C) from the same patient used in panel B.
Figure 2 Protein expression levels of FGFR3 and TP53 in bladder tumor tissue. (A) Haematoxylin-Eosin staining of a papillary tumor.
Original magnification ×20. (B) High levels of FGFR3 expression with a cytoplasmic and membranous patter. Original magnification ×40. (C) Low
TP53 immunostaining of tumor cells showing a nuclear pattern. Original magnification ×20.
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Exogenous risk factors that could have contributed
to BC in our patient are smoking, exposure to diesel
exhaust and depleted uranium (DU). First our patients
smoking status is 5.5 pack-years, which is known to be
associated with an increased risk of BC. Secondly, a
meta-analysis of BC and diesel exhaust exposure
demonstrated a relative risk of 1.44 for occupations
exposed to high diesel fume levels [14]. Our patient
worked as a driver of a diesel armed truck and was
exposed to diesel exhaust fumes, working in a valley
were the fumes were retained in a cloud of exploded
ammunition. Lastly, although some believe that there
is a link between exposure to DU and cancer develop-
ment no hard evidence has been found to support this
hypothesis. While evidence from Hiroshima data
shows a latency period of 10-15 years to develop can-
cer this concerns an acute high-dose exposure and
other studies were not able to demonstrate this link in
Balkan veterans [15,16]. On the other hand two studies
by Miller et al. demonstrated in vitro tumorigenic
transformation of osteoblasts when exposed to DU
[17,18].
Figure 3 Overview of copy number alterations for all chromosomes. Red: loss, green: gain.
Figure 4 Age related occurrence of BC due to exposure to carcinogenic factors and BC-associated genetic changes. (A) Young BC
patients, age <20, with a low carcinogenic exposure having chromosomal stable tumors, no mutations in FGFR3 and TP53 and no loss on
chromosome 9. (B) Patients aged 20-60 with either a molecular profile corresponding to young (<20) or older (>60) patients. (C) Older BC
patients with high exposure to carcinogenic factors and chromosomal unstable tumors, loss on chromosome 9, FGFR3 and TP53 mutations.
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Since Van der Aa et al. demonstrated that specifically
young patients perceive a cystoscopic investigation as
burdensome this emphasizes the need for patient strati-
fication [19]. To determine whether a young BC patient
should be monitored according to the standard follow-
up protocol or can be monitored less frequently by
cystoscopy, we propose to determine the FGFR3 muta-
tion status of the primary tumor. One possibility is that
the tumor will have few genetic changes and secondly
that the tumor will have genetic changes comparable to
those found in older patients (Figure 4B, 4C). Mutations
in FGFR3 are tumor-specific and are not found in nor-
mal tissue, meaning that detection of a mutation in
voided urine indicates the presence of tumor cells in the
urinary tract. The results of the follow-up in time for
our patient are indicated in Additional file 1. We
demonstrate that the S249C mutation in FGFR3
detected in the tumor was also detected in the urine
(Figure 1C), indicating that the detected tumor cells
were shed by the resected tumor. Our results demon-
strate that urine cytology does not detect the tumor in
two cases, which is in concordance with previous studies
that demonstrate a low sensitivity of urine cytology for
the detection of tumors of low stage and grade [20,21].
Although this concerns just one patient, our results
imply that patient monitoring by FGFR3 mutation ana-
lysis could be a feasible non-invasive method in the fol-
low-up of young NMI-BC patients presenting with a
mutation in FGFR3 and indicate that future research is
required to investigate this.
Conclusions
Multiple studies demonstrate the relatively benign dis-
ease course of bladder tumors in young patients, but
there are some cases with a high recurrence rate and a
progression rate comparable to older patients. We pre-
sent a young patient having multiple multifocal recur-
rent bladder tumors with molecular characteristics
found in older patients. It would be of interest to per-
form molecular studies in a larger subset of patients to
elucidate whether these tumors comprise a biologically
distinct group. Since BC tumors rarely present in
young patients, a multicenter collaboration would be
needed for investigation. This could ultimately lead to
stratification of patients that need close monitoring
and patients with favorable molecular characteristics of
the tumor that can be monitored less frequently,
hereby decreasing the number of cystoscopies per-
formed in young patients who specifically perceive a
cystoscopy as burdensome. For the follow-up of young
patients presenting with an FGFR3 mutant NMI
tumor, FGFR3 mutation analysis could be a feasible
alternative for recurrence detection.
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